Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Aung Tun, Matthew Frank, Madiha Iqbal, Alex Herrera, Mehdi Hamadani, Waleska Pérez, Soyoung Kim, Babatunde Adedokun, Constance Lau, Kenny Hu, Timothy Best, Olga Nikolajeva, Grace Lee, Marcelo Pasquini, Caron Jacobson

Blood (2025) 146 (Supplement 1): 5356.

https://doi.org/10.1182/blood-2025-5356

Published: 2025

Journal Articles

Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers

Olalekan Oluwole, Pardis Lakzadeh, Constance Lau, Steve Kanters, Genevieve Meier, Hil Hsu, Sean Harrigan, Graeme Ball, Samuel Hong, Evan Popoff

Blood (2025) 146 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2025-4411

Published: 2025

Journal Articles

Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US)

Olalekan Oluwole, Hil Hsu, Samuel Hong, Karl Kilgore, Graeme Ball, Kelly Birch, Constance Lau, Genevieve Meier, Christie Teigland, Kiran Sunkari

Blood (2025) 146 (Supplement 1): 6284.

https://doi.org/10.1182/blood-2025-6284

Published: 2025

Journal Articles

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ran Reshef, Constance Lau, Hil Hsu, Brett Doble, Clare Spooner, Anik R Patel, Liana Nikolaenko

Blood (2024) 144 (Supplement 1): 7775.

https://doi.org/10.1182/blood-2024-200288

Published: 2024

Journal Articles

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Ahmed Sawas, MD, Constance Lau, MPH, Michael Thomson, MS, Kathleen Maignan, NP, MSN

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141274

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers

Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US)

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Email alerts

ASH Publications

American Society of Hematology

Update search

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers

Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US)

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only